Trial Information

Compassionate Treatment of Advanced Cancer With Amplitude-Modulated Electromagnetic Fields

We have previously shown that the intrabuccal administration of low and safe levels of
electromagnetic fields, amplitude-modulated at a frequency of 42.7 Hz by means of a
battery-powered portable device modifies the electroencephalographic activity of healthy
subjects (1, 2) and is associated with subjective and objective relaxation effects (3).
These results prompted us to study the effects of the 42.7 Hz frequency in patients
suffering from insomnia. A randomized control trial did not reveal any difference between
42.7 Hz treatment and placebo (4) but sequential administration of four insomnia-specific
frequencies, including 42.7 Hz, resulted in a significant decrease in sleep latency and a
significant increase in total sleep time in patients suffering from chronic insomnia (5).
Dosimetric studies have shown that the amount of electromagnetic fields delivered to the
brain of patients with this approach is 100 to 1000 times lower than the amount of
electromagnetic fields delivered by handheld cellular phones and do not result in any
heating effect within the brain (4). The U.S. FDA has determined that such a device is not a
significant risk device. Lastly, a long-term follow-up survey of 807 patients who have
received this therapy revealed that the rate of adverse reactions were low and were not
associated with increases in the incidence of malignancy or coronary heart disease (6).

Given the advantageous safety profile of athermal, non-ionizing radiofrequency
electromagnetic fields and the emerging evidence that low levels of electromagnetic or
electric fields may modify the growth of tumor cells (7-9), we decided to test the
hypothesis that low levels of electromagnetic fields modulated at tumor-specific frequencies
may alter the growth of human malignancies. We have developed a novel patient-based
biofeedback method with the goal to identify cancer-specific frequencies and have examined
patients with this approach. Following identification of such frequencies in a total of 163
patients, we will offer compassionate treatment to 28 patients with advanced cancer and
limited palliative therapeutic options.